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Abstract: Two problems now threaten the future of anticancer drug development: (i) the information explosion has made research into 
new target-specific drugs more duplication-prone, and hence less cost-efficient; and (ii) high-throughput genomic technologies have 
failed to deliver the anticipated early windfall of novel first-in-class drugs. Here it is argued that the resulting crisis of blockbuster drug 
development may be remedied in part by innovative exploitation of informatic power. Using scenarios relating to oncology, it is shown 
that rapid data-mining of the scientific literature can refine therapeutic hypotheses and thus reduce empirical reliance on preclinical 
model development and early-phase clinical trials. Moreover, as personalised medicine evolves, this approach may inform biomarker-
guided phase III trial strategies for noncytotoxic (antimetastatic) drugs that prolong patient survival without necessarily inducing tumor 
shrinkage. Though not replacing conventional gold standards, these findings suggest that this computational research approach could 
reduce costly ‘blue skies’ R&D investment and time to market for new biological drugs, thereby helping to reverse unsustainable drug 
price inflation.
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Introduction
The development of massive online text archives and 
biomedical data warehouses over the last decade has 
created new opportunities to mine useful information 
from fuzzy datasets comprising both statistical and 
semantic information.1–3 Association rules have been 
developed to extend fuzzy set theory to text-mining; 
at  the  simplest  level,  identification  of  a  given  set 
(e.g. both A and B not C) at higher-than-expected 
frequency  provides  support  for  the  probability  of 
a causal link between A and B in the absence of C, 
albeit with varying confidence levels quantifiable as 
membership functions or degrees of truth. The non-
digital algorithms so derived may generate value from 
masses of noisy data, in effect representing Bayesian 
interpretations  of  semantic  information.4  Examples 
include tracking of influenza epidemics from search 
engine  patterns,5  the  epidemiologic  surveillance  of 
AIDS,6  monitoring  of  the  blogosphere,7  academic 
publication  analysis,8  and  assessment  of  scientific 
merit based on impact factors.9
The causality of such associations gleaned from 
text-mining  of  the  oncology  literature  is  readily 
illustrated a posteriori. Based on existing knowledge 
we predict, for example, that the association of the 
string {papillomavirus} with {cervical cancer} will be 
greater than with {nasopharyngeal cancer}, whereas 
the  reverse  will  be  true  for  {Epstein-Barr  virus}. 
Similarly, we may infer that lung cancer is more lethal 
than breast cancer, given that the texts {lung cancer} 
and {mortality} associate 50% more often than {breast 
cancer}  and  {mortality},  whereas  the  association 
between  these  diseases  and  {incidence}  is  similar 
(χ2 = 1059.99,  df = 1,  p  0.01;  Supplement S1). 
The  “efficient  citation  hypothesis”  so  implied  can 
be used to test research strategies that are becoming 
impractically slow and/or expensive to validate using 
historical approaches.
New  anticancer  drug  development,  by  virtue  of 
its target-specific nature, should readily lend itself to 
such semi-digital analysis.10 Returns on investment in 
applied cancer research have been declining in recent 
years due to a decline of blockbuster drug frequency.11 
This has led in turn to progressive escalation of the 
cost for bringing a therapeutic to market, which now 
approaches  US$1bn  per  FDA-licensed  product;12 
such expense is in turn handed on to the health-care 
consumer.13 Part of this cost relates to the inefficiency 
of the modern clinical trial system, for which problem 
many investigators are seeking fresh approaches such 
as  multi-arm  designs,14  personalized  medicine  or 
pharmacodiagnostics.15 A related problem specific to the 
cancer field is that selection of drugs for costly phase III 
trials  remains  based  exclusively  on  demonstration 
of drug ‘activity’ quantified as tumor shrinkage, or 
response.16  This  endpoint,  although  convincingly 
associated  with  short-term  therapeutic  benefit,  may 
lack sensitivity for detecting the metastasis-inhibiting 
activity of non-tumorilytic drugs—which could well 
correlate strongly with survival benefit, and be better 
predicted  by  biomarker  expression.17  Hence,  the 
present study seeks to test how low-cost text-mining 
may improve applied cancer research feasibility while 
reducing investment risk.
Methods
Searches were undertaken using the latest text-based 
search-and-retrieval  version  of  PubMed—a  service 
of the National Library of Medicine developed by the 
National Center for Biotechnology Information used 
to  integrate  the  major  databases  (including  PubMed 
Central, Journals, Books, OMIM). The Entrez cross 
database search page was used to access the Entrez 
Global Query database search engine. A search across 
the Entrez database was performed by entering one or 
more search term(s) or phrase(s) to execute the search.
Using  this  approach,  the  PubMed  database  was 
serially interrogated using the terms representing both 
the primary set of interest (P) and the secondary sets 
of interest (S1, S2, etc.), resulting in identification of 
the common set of interest (C1, C2, etc.). Arithmetical 
correction was made for different frequencies of S1, S2, 
etc., permitting calculation of the expected value of C 
for a given S intersection given knowledge of previous 
values of C and assuming the null hypothesis. The 
ratio of C2 to C1 was then considered the multiplier 
(M2) by which the null hypothesis for S2 (compared 
to S1) was tested. Non-parametric statistical analysis 
was performed by chi-square calculation.
Results
An  initial  example  of  how  disease  biology  or 
phenotype can be predicted by text-mining is presented 
in Figure 1 and Supplement S2, which illustrate that 
the clinical complication of finger clubbing is more 
often associated with lung tumors of either squamous Online analysis of published research
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cell  carcinoma  or  adenocarcinoma  histology  than 
with small-cell tumors (χ2 = 37.96, df = 2, p  0.01). 
Similarly, it is possible to show that {brain metastasis} 
text in breast cancer is 80-fold more strongly associated 
with tumor HER2 expression than with ER expression 
(χ2 = 73.461, df = 1, p  0.01; Supplement S3A). By 
the same token, {peritoneal carcinomatosis} is more 
often associated with primary invasive lobular cancers 
than with invasive ductal cancers (χ2 = 18.75, df = 1, 
p  0.01), as is the molecule {E-cadherin} (χ2 = 92.98, 
df = 1,  p  0.01;  Supplement  S3B),  expression  of 
which is known to be selectively lost in the former 
tumor  type.  In  contrast,  there  is  no  significant 
difference  between  the  frequency  of  association  of 
{E-cadherin} and {peritoneal metastases} (χ2 = 0.42, 
df = 1,  p = 0.5169;  Supplement  S3B),  consistent 
with the possibility that these molecular and clinical 
terms are causal co-variables. Such text associations 
can thus generate or support hypotheses concerning 
biomarkers in a way that may be relevant to designing 
therapeutic strategies in clinical research.
Molecular biological issues may also be addressed 
by text-mining which shows, for example, that the 
p53  signalling  (apoptotic)  pathway  is  70%  more 
strongly associated with the ARF gene of the two-gene 
CDKN2A locus than is its INK4A partner (χ2 = 63.19, 
df = 1, p  0.01; Supplement S4); this suggests that 
these  two  sub-genes  mediate  distinct  cell  choices 
relating to cell death vs. cell-cycle delay/repair, which 
could  prove  relevant  to  biomarker  development. 
Such  an  approach  can  be  extended  to  mapping 
multiple phenotypes, both clinical and molecular, as 
depicted in Figure 2; the ‘word picture’ so created 
by desktop text-mining is used here to polarize the 
phenotypes of two otherwise generic clinical entities, 
adenocarcinoma and squamous cell carcinoma.
This strategy can be further applied to questions 
relating to clinical trial design. Imagine, for example, 
that  there  are  two  novel  candidate  anticancer 
therapeutics:  one  is  an  antagonist  to  insulin-like 
growth factor-1 (IGF1), and the other an inhibitor 
of signalling via the hepatocyte growth factor (HGF, 
scatter factor, c-met ligand) pathway. A simple text-
mining  search  shows  that  HGF  is  eight-fold  more 
strongly associated with tumor metastasis, whereas 
IGF1 is three times more strongly associated with 
drug  resistance  (χ2 = 564.15,  df = 1,  p  0.01; 
Supplement S5). Such data may reasonably suggest to 
an oncologist that clinical trials of the HGF antagonist 
should test the hypothesis that it reduces metastasis 
in one or more tissue sites—either by reducing time 
to  progression  and/or  improving  overall  survival, 
perhaps  when  used  as  a  maintenance  or  adjuvant 
therapy18—rather than judging it solely on the basis 
of tumor shrinkage in progressive metastatic disease 
(see below). The IGF1 inhibitor, on the other hand, 
may be best used concurrently with chemotherapy as 
a sensitizer in metastatic or neoadjuvant settings, in 
which contexts tumor shrinkage may be a sensitive 
measure of its value.
Table 1 provides another illustration of hypothesis 
generation  relevant  to  clinical  trials  using  similar 
secondary  data  sets.  In  this  case,  a  company  has 
drugs of two classes, either tyrosine kinase inhibitors 
(TKIs)  or  metalloprotease  inhibitors  (MPIs).  The 
question is again raised: is there any difference in the 
respective likelihoods that one drug class will be more 
active in causing tumor responses (i.e. antagonizing 
replication) while the other may be less active in its 
antimitogenic action but more active in suppressing 
metastasis? As shown, the text-mined association of 
MPIs with antimetastatic (vs. antiproliferative) key 
words is 6.5-fold that of TKIs, whereas the reverse 
trend is true for antiproliferative terms (χ2 = 2099.6, 
df = 1,  p  0.01);  the  multiplicative  difference  of 
the two trends is about 15-fold (as is true for the 
strings {kinase} and {protease} alone, χ2 = 4889.64, 
df = 1, p  0.01; Supplement S6). Hence, one could 
squamous 
cell lung 
cancer
small-cell 
lung 
cancer
lung 
adeno- 
carcinoma
finger
clubbing
Figure  1.  schematic  illustration  of  a  text-mined  association.  The 
extent  to  which  a  phenotype  such  as  finger  clubbing  is  associated 
with a specific lung cancer histology may be estimated by association 
(see supplement s2), as visualized here.epstein
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reasonably hypothesise that clinical trials evaluating 
the  anticancer  efficacy  of  protease  inhibitors  may 
(i)  best  evaluate  parameters  relevant  to  metastasis 
prevention  (e.g.  time  to  progression)  rather  than 
response, and (ii) use maintenance/adjuvant rather than 
induction schedules in their clinical trial designs.
This approach could also be applied to prediction 
of  targeted  drug  efficacy  for  different  disease 
subtypes prior to the advent of a validated biomarker. 
Consider  the  scenario  in  which  a  company  has  a 
promising mTOR pathway inhibitor and is wanting 
to  prioritise  its  phase  2–3  clinical  trial  strategy. 
Since the Akt proto-oncogene is an important node 
in the mTOR signalling network, we may begin by 
characterising the text-mined associations of different 
tumor subtypes with Akt; this analysis shows that the 
strongest association is with prostate cancer (Table 2). 
In contrast, when assessing the associations of the 
mTOR pathway inhibitor temsirolimus, the strongest 
association is with its licensed indication in renal cell 
carcinoma. Although not surprising, this difference 
raises  the  commercially  relevant  hypothesis  that 
a ‘second use’ for mTOR inhibitors could well be 
confirmed for other malignancies including, though 
not limited to, prostate cancer.
The associations of different treatment approaches 
with  text-mined  costs  and  benefits  may  also  be 
compared  using  this  seamless  approach.  Figure  3 
shows  the  comparative  quantitative  associations 
of the secondary variable {overall survival benefit) 
with the primary variables of either {adjuvant cancer 
therapy} in column 1, {palliative cancer therapy} in 
column 2, {maintenance cancer therapy} in column 3, 
or  {preventive  cancer  therapy}  in  column  4,  and 
reveals  a  steady  decline  in  that  order.  In  contrast, 
this  trend  is  reversed  when  {cost-effectiveness}  is 
substituted as the secondary variable. This striking 
difference  suggests  that  third-party  payers  could 
scrutinize the value of adjuvant treatment claims more 
intensively, while subsidizing preventive interventions 
for healthy individuals with greater enthusiasm. For 
companies under pressure to prove survival benefits 
for product licensing, on the other hand, these data 
suggest that drugs used in palliative or maintenance 
settings may deliver more easily defended ratios of 
QALY to unit cost than adjuvant studies (as well as 
being cheaper to conduct in the first instance). The 
possibility  is  also  raised  that  biologically-targeted 
preventive agents could become the backbone of the 
blockbuster drug market.
Discussion
The central finding of this study is an exciting one 
for  modern  researchers:  namely,  that  the  sudden 
availability  of  huge  online  text-based  databases 
permits novel, cheap and potentially important research 
to  be  conducted  by  computer-based  researchers, 
thereby  expanding  the  scope  and  accessibility  of 
research methodology. Moreover, by extending this 
approach, innovative informatics strategies may be 
developed and automated over time to derive value 
from otherwise wasted informational resources. This 
is true not only for curiosity-driven academic research 
but,  as  shown  here,  also  for  commercially-driven 
applied science.
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Figure  2.  Phenotypic  distinction  of  ‘adenocarcinoma’  vs.  ‘squamous 
carcinoma’ using text-mining; for each phenotype shown, the PubMed 
database  was  exclusively  interrogated  (e.g.  adenocarcinoma  nOT 
squamous cell carcinoma, and vice versa). The figures on the horizontal 
axis represent the multiplier (M) by which each phenotype is preferentially 
associated with the histology labelled on the adjacent vertical axis.
Table  1.  Text-mined  associative  phenotyping  of  drug 
action. TKIs  are  more  strongly  associated  with  {growth 
and replication} than MPIs, whereas the reverse appears 
true  of  {invasion  and  metastasis}  (χ2 = 2099.6,  df = 1, 
p  0.01).
AnD (growth  
OR replication)
AnD (invasion  
OR metastasis)
Tyrosine kinase 
inhibitor (n = 20118)
10741 1010
Metalloprotease 
inhibitor (n = 12790)
3063 1877Online analysis of published research
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It must be emphasized, however, that numerous 
pitfalls  await  the  unwary  who  seek  to  ascribe 
causality  to  text  associations  without  rigorous 
exclusion  of  confounders  (to  appreciate  this,  one 
has only to consider the famous ‘beer-and-diapers’ 
market research anecdote).19 The challenges include 
unambiguous  identification  of  genes  or  other 
molecules, leading to false-positive data inclusions, 
and failure of current text-mining systems to achieve 
100% recall, leading to false-negative loss of sensitivty. 
Hence,  unless  carefully  excluded,  synonyms  and 
name variations may cause significant problems with 
the accuracy of text-based data mining.
An additional problem relates to system ‘noise’ 
which, in any text-mined database, may be expected 
to increase as the age of the data archive increases. 
To address the confounding effect of ageing data will 
involve inevitable compromises between database size 
and data novelty; on the other hand, more recent data 
may be subject to dispute or lack of replication, so may 
be less reliable than more durable (and hence, text-
repetitive) data. A further limitation is that text terms 
may change over time, with molecules or drugs being 
renamed,  or  having  different  names  in  different 
languages or countries. Such limitations require prior 
knowledge on the part of the investigator(s) to enable 
corrective action in anticipation.
How can a purely text-mining approach distinguish 
positive  and  negative  associations?  A  given 
article  examining  two  variables  may  not  report 
a  simple  positive  association,  but  rather  the  lack 
of  an  association  or  even  an  inverse  or  negative 
association;  text-mining  will  not  distinguish  these 
contingencies,  however.  In  general,  however,  it  is 
reasonable  to  assume  that  positive  associations 
will  vastly  outnumber  negative  associations  when 
measured by text-mining, if only because negative 
associations tend to be less interesting to readers (and 
hence to journals and publishers) who may in general 
be keener to understand causality than exceptions or 
confounders.
Notwithstanding  these  important  caveats, 
it  is  becoming  clear  that  improved  knowledge 
management  is essential to regaining momentum in 
pharmaceutical R&D,20 and this unmet need requires 
fresh approaches. The advantages of the text-mining 
approach described here are that it is simple, cheap, 
fast,  objective,  and  powerful.  Its  disadvantages 
are at least as plentiful, but perhaps the main ones 
are (i) that it is easily confounded by overlooking 
nonrandom associations which may not be obvious to 
all investigators, and (ii) that careful thought and broad 
Table 2. Association of tumor subtypes with a putative surrogate biomarker for the mTOr pathway, Akt, showing that the 
strongest association is with prostate cancer. As expected, the much stronger correlation of the mTOr inhibitor temsirolimus, 
which is already licensed for use in renal cell cancer, is with the latter malignancy. P, primary set size; C, intersecting set 
size.
Breast 
cancer
Renal 
cancer
colorectal 
cancer
prostate 
cancer
Lung 
cancer
endometrial 
cancer
P 196883 75450 117408 78484 166465 20194
AnD Akt 1208 152 349 719 638 117
(100 × C) 0.61 0.20 0.30 0.92 0.38 0.58
AnD temsirolimus 26 129 3 8 3 3
(100 × C) 0.01 0.17 0.003 0.01 0.002 0.015
Adjuvant 
0
40
80
120
Palliative  Maintenance  Preventive 
Figure 3. Text-mined comparison of survival vs. cost data for different 
cancer treatment modes, suggesting that adjuvant therapies are most 
strongly  linked  to  survival  benefit  (open  columns)  but  least  to  cost-
effectiveness (solid columns), whereas preventive treatments have the 
opposite  associations.  Palliative  and  maintenance  treatments  appear 
intermediate for both secondary endpoints.epstein
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background knowledge are needed to frame a series of 
questions that can provide a useful association. These 
limitations are sufficiently serious to restrict the use 
of such approaches for now to hypothesis generation, 
but it seems reasonable to expect that methodologic 
refinement and practical experience will lead to far 
more sophisticated approaches that will eventually be 
incorporated into routine research practice. Indeed, it 
may even become possible to devise programs that 
scan scientific literature and experimental data in the 
background, generating associations and hypotheses 
at different thresholds of certainty and improbability 
(creativity). In some ways this would be an expected 
outcome  of  the  information  explosion  which  now 
produces more data than any individual can hope to 
absorb and evaluate.21
The  examples  given  here  relate  to  the  field  of 
oncology,  but  could  just  as  readily  be  applied  to 
other  therapeutic  areas  such  as  cardiovascular  or 
neurological disease. In the same way that credit card 
companies  and  search  engines  now  scan  electronic 
data for commercially useful patterns, so can scientists 
now  begin  looking  beyond  their  own  laboratory 
benches in an effort to exploit the informatic power of 
modern databases. Although the challenges of text-data 
specificity and sensitivity are not to be underestimated, 
we may discover that the fruits of the genomic revolution 
will be greater than any of us can yet conceive.
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Table s1. Data upon which the conclusions in paragraph 2 of the Introduction are based.
AnD incidence AnD mortality
Breast cancer (197552) 39175 19733
Lung cancer (166982) 33320 24871
(39318) (29348)
M 1.18 (ns) 1.49
Text associations suggesting that lung cancer is a significantly more lethal disease than is breast cancer (χ2 = 1059.99, df = 1, p  0.01).
Table s2. Text data upon which figure 1 is based.
AnD AnD M
Lung cancer squamous cell carcinoma 16493 Finger clubbing 54 3.27
small-cell carcinoma 34255 42 1.23
Adenocarcinoma 28885 101 3.50
Text-mining data showing that {small-cell lung cancer} is significantly less often associated with {finger clubbing) than are the other two histologic labels 
(χ2 = 37.96, df = 2, p  0.01).
Table s3A. Text-mined data alluded to in the text of para 1, results. Text association of her2 expression in breast cancer 
with brain metastasis.
AnD HER2-positive AnD ER-positive
Breast cancer 473 2037
AnD Brain metastases 19 1
M1 4.02 0.05
M2 80.4
Data set showing a significantly stronger association of {brain metastases} in {breast cancer} associated with the term {HER2-positive} than with 
{er-positive) (χ2 = 73.461, df = 1, p  0.01).
Table s3B. Association of lobular breast cancer histology and {e-cadherin} text string with peritoneal metastasis.
AnD invasive ductal AnD invasive lobular
Breast cancer 13310 4649
AnD Peritoneal metastases 28 30
Breast cancer 13310 4649
AnD E-cadherin 243 209
E-cadherin 243 209
AnD Peritoneal metastases 28 30
χ2 = 18.75, df = 1, p  0.01.
χ2 = 92.98, df = 1, p  0.01.
χ2 = 0.42, df = 1, p = 0.5169.
Data  showing  stronger  association  of  {invasive  lobular  cancer}  with  {peritoneal  metastases}  than  with  {invasive  ductal  cancer},  while  implicating 
{e-cadherin} as a molecular co-variable of this clinical relationship (see text).
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Table s6. Text comparison of ‘kinase’ and ‘protease’ strings 
as  an  association  of  pro-replicative  vs.  pro-metastatic 
terminology (see also Table 1).
AnD (growth OR 
replication OR mitosis)
AnD (migration 
OR motility OR 
metastasis)
Kinase 147941 23748
Protease 44028 15732
Quantification of text-mined molecular phenotype: there is a greater than 
16-fold difference in the association of ‘kinase’ with pro-mitogenic vs. 
pro-metastatic  key  words  when  compared  with  the  corresponding 
associations of ‘protease’ (χ2 = 4889.64, df = 1, p  0.01).
Table s5. Data suggesting a stronger association between 
hgF  and  metastasis,  and  between  IgF-1  and  drug 
resistance.
Insulin-like 
growth factor-1
Hepatocyte 
growth factor
Drug resistance 319 100
Metastasis 100 815
Data  showing  significantly  stronger  association  of  {metastasis}  with 
{hgF} than with {IgF1}, but stronger association of {drug resistance} with 
IgF1 than with hgF (χ2 = 564.15, df = 1, p  0.01).
Table  s4.  Text-mined  data  showing  the  association 
between ARF and p53, compared to that between INK4A 
and p53.
CDKN2A AnD INK4A AnD ARF
no p53 4794 772
+p53 1568 429
Text-mined data showing a significantly stronger association of {p53} 
with {ARF} than with {INK4A}. (χ2 = 63.19, df = 1, p  0.01).